Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis

NCT00783718 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

895

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis

Interventions

DRUG: vedolizumab
OTHER: Placebo

Sponsor

Millennium Pharmaceuticals, Inc.